SVB Securities analyst Marc Goodman downgraded Aptinyx to Market Perform from Outperform with a price target of 50c, down from $2.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APTX:
- APTX Nosedives after Parkinson’s and Dementia Phase 2 Study Disappoints
- Aptinyx to resume trading at 4:35pm E.T.
- Aptinyx says Phase 2 Study of NYX-458 did not demonstrate sufficient efficacy
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue